BIOGEN INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
BIOGEN INC. (BIIB) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $1.23 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-06
- BIOGEN INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $1.23B, a 43.57% increase from fiscal 2024.
- BIOGEN INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $853.40M, a 343.56% increase from fiscal 2023.
- BIOGEN INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $192.40M, a 89.55% decline from fiscal 2022.
- BIOGEN INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $1.84B, a 310.89% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $1.23B 10-K · filed 2026-02-06 |
| 2024-12-31 | $853.40M 10-K · filed 2026-02-06 |
| 2023-12-31 | $192.40M 10-K · filed 2026-02-06 |
| 2022-12-31 | $1.84B 10-K · filed 2025-02-12 |
| 2021-12-31 | $448.30M 10-K · filed 2024-02-14 |
| 2020-12-31 | $3.29B 10-K · filed 2023-02-15 |
| 2019-12-31 | $4.73B 10-K · filed 2022-02-03 |
| 2018-12-31 | $3.88B 10-K · filed 2021-02-03 |
| 2017-12-31 | $3.54B 10-K · filed 2020-02-06 |
| 2016-12-31 | $3.66B 10-K · filed 2019-02-06 |
| 2015-12-31 | $3.39B 10-K · filed 2018-02-01 |
| 2014-12-31 | $2.56B 10-K · filed 2017-02-02 |
| 2013-12-31 | $1.95B 10-K · filed 2016-02-03 |
| 2012-12-31 | $1.40B 10-K · filed 2015-02-04 |
| 2011-12-31 | $1.41B 10-K · filed 2014-02-06 |
| 2010-12-31 | $846.40M 10-K · filed 2013-02-05 |
| 2009-12-31 | $1.07B 10-K · filed 2012-02-03 |
| 2008-12-31 | $829.20M 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |